Company: LIMN
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001104659-25-010605
Chunk: 267

Company: Liminatus Pharma, Inc.
Filing Date: 2025-02-07
Form: 424B3
Chunk 267
---
 the recommendation of the Iris Board in favor of approval of the Incentive Plan, you should keep in mind that certain members of the Iris Board and officers have interests in the Incentive Plan that are different from, or in addition to, your interests as a stockholder or warrant holder, including, among other things, the potential future issuance of awards to officers and directors of the Combined Company.

#### Required Vote for Approval
The approval of the Incentive Plan Proposal requires the affirmative vote of a majority of the votes cast by stockholders present in person or represented by proxy and entitled to vote thereon at the Special Meeting (which would include presence by virtual attendance at the Special Meeting). An abstention will be counted towards the quorum requirement but will not count as a vote cast at the Special Meeting. A broker non-vote will neither be counted towards the quorum requirement (as we believe the Incentive Plan Proposal will be considered as non-discretionary) nor count as a vote cast in the Special Meeting.

Adoption of the Incentive Plan Proposal is conditioned on the approval of the Business Combination Proposal, the Election of Directors Proposal, and the Nasdaq Proposal at the Special Meeting.

The closing is conditioned on the approval of the Business Combination Proposal, the Election of Directors Proposal, the Incentive Plan Proposal and the Nasdaq Proposal at the Special Meeting.

#### Recommendation of the Iris Board
<div align='center'>THE IRIS BOARD UNANIMOUSLY RECOMMENDS THAT IRIS STOCKHOLDERS VOTE “FOR” THE APPROVAL OF THE INCENTIVE PLAN PROPOSAL.

130</div>

TABLE OF CONTENTS

#### PROPOSAL NO. 4 — THE PARENTCO CHARTER PROPOSAL

### Overview
In connection with the Business Combination, Iris is asking its stockholders to approve the adoption of the ParentCo Certificate of Incorporation in the form attached to this proxy statement/prospectus as Annex C , which, in the judgment of the Iris Board, is necessary to adequately address the needs of Liminatus following the consummation of the Business Combination.

The following is a summary of the key changes between the Iris Certificate of Incorporation and the ParentCo Certificate of Incorporation. This summary is qualified by reference to the complete text of the ParentCo Certificate of Incorporation. All stockholders are encouraged to read the ParentCo Certificate of Incorporation in its entirety for a more complete description of its terms.

• Name Change . Change the corporate